OS and DFS by 1% NPM1^mut/ABL1 cutoff. MRD clearance or MRD reduction ≤1% after completion of study treatment translated clinically into a better (A) DFS and (B) OS. The subgroup with >1% MRD displayed a significantly worse outcome in comparison with the negative and <1% subgroups. Note that the DFS analysis started from the time of completion of the study treatment.